Investment
Features
FeesSafety
Academy
More
Pluang+

U.S. testing begins for needle-free tirzepatide patch targeting $66B GLP-1 market

Market News
13 Oct 2026
Newsfile Corp
View Source
Bullish
U.S. testing begins for needle-free tirzepatide patch targeting $66B GLP-1 market

The Precision Peptide Company has started formal U.S. testing of its needle-free tirzepatide GLP-1 transdermal patch, designed to deliver the drug without needles or refrigeration. This innovation targets the $66 billion global GLP-1 market, which is expected to grow to $185.3 billion by 2033. The patch aims to improve patient adherence by eliminating needle fear and cold storage needs, potentially expanding usage beyond current injectable products that generated $36.5 billion in 2025. The company plans to advance to commercial production pending successful test results.

The Precision Peptide Company's needle-free GLP-1 tirzepatide patch enters formal U.S. testing amid a health sector where 80 of 128 Pluang-traded US stocks rose today. As of Oct 13, 2026 16:51 WIB, notable movers include Sanofi SA (SNY) at USD 40.52 with 74% buy orders and a typical hold time of 94 days, Tilray Brands Inc (TLRY) at USD 3.30 with 99% buy orders, and Incyte Corporation (INCY) at USD 109.38 with 100% buy orders. This snapshot reflects active investor interest in health-related stocks on Pluang.

More News

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...

Analyst Insights
Bullish
49 minutes ago
Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...

Company Fundamentals
Bullish
57 minutes ago
TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC's preliminary Q3 2026 revenue reached approximately NT$1.49 trillion, about 50% higher year-over-year and above management guidance, driven by strong AI chip demand. The company holds a dominant 73% share of the global pure-play foundry market, ...

Company Fundamentals
Bullish
1 hour ago
Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey have launched Growth Signals, a new initiative to regularly poll entrepreneurs and business leaders of fast-growing companies. This program aims to capture their priorities, challenges, and growth outlook to inform Inc.'s editor...

Others
Neutral
1 hour ago
BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard Corporation has launched a new corporate website featuring an expanded treasury dashboard that updates its Adjusted Net Asset Value and other key financial metrics intraday. This move aims to increase transparency and accountability in t...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App